Ondansetron as an adjunctive therapy in positive, negative and cognitive symptoms of schizophrenia.
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2023/04/052140
- Lead Sponsor
- Central Institute of Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Inpatients satisfying the ICD 10-DCR [1993] criteria for schizophrenia
2.Current positive symptoms rated >=4 (moderate) on one or more of these BPRS items: conceptual disorganization, grandiosity, hallucinatory behaviour and unusual thought content.
3.Age 18 - 60 years of both sexes.
4.Illness duration of equal to or more than 2 years.
5.Those who give informed consent for participating in the study
1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
2.Known hypersensitivity to Tab. Ondansetron or any of its components.
3.Receiving concomitant Apomorphine.
4.Deranged liver function test (Alanine transaminase >= 180 IU/l and/or Aspartate transaminase >= 140 IU/l).
5.Significant current/past medical or neurological illness including severe hepatic disease and history of severe head injury.
6.Patients who received ECT in the last 6 months or currently receiving ECT.
7.QTc interval >= 450ms in males and >= 470ms in females on Electrocardiogram (ECG).
8.Pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method